TY - JOUR
T1 - Considerations for the Use of Phage Therapy in Clinical Practice
AU - Suh, Gina A.
AU - Lodise, Thomas P.
AU - Tamma, Pranita D.
AU - Knisely, Jane M.
AU - Alexander, Jose
AU - Aslam, Saima
AU - Barton, Karen D.
AU - Bizzell, Erica
AU - Totten, Katherine M.C.
AU - Campbell, Joseph L.
AU - Chan, Benjamin K.
AU - Cunningham, Scott A.
AU - Goodman, Katherine E.
AU - Greenwood-Quaintance, Kerryl E.
AU - Harris, Anthony D.
AU - Hesse, Shayla
AU - Maresso, Anthony
AU - Nussenblatt, Veronique
AU - Pride, David
AU - Rybak, Michael J.
AU - Sund, Zoe
AU - Van Duin, David
AU - Van Tyne, Daria
AU - Patel, Robin
N1 - Publisher Copyright:
© 2022 American Society for Microbiology. All rights reserved.
PY - 2022/3
Y1 - 2022/3
N2 - Increasing antimicrobial resistance and medical device-related infections have led to a renewed interest in phage therapy as an alternative or adjunct to conventional antimicrobials. Expanded access and compassionate use cases have risen exponentially but have varied widely in approach, methodology, and clinical situations in which phage therapy might be considered. Large gaps in knowledge contribute to heterogeneity in approach and lack of consensus in many important clinical areas. The Antibacterial Resistance Leadership Group (ARLG) has convened a panel of experts in phage therapy, clinical microbiology, infectious diseases, and pharmacology, who worked with regulatory experts and a funding agency to identify questions based on a clinical framework and divided them into three themes: potential clinical situations in which phage therapy might be considered, laboratory testing, and pharmacokinetic considerations. Suggestions are provided as answers to a series of questions intended to inform clinicians considering experimental phage therapy for patients in their clinical practices.
AB - Increasing antimicrobial resistance and medical device-related infections have led to a renewed interest in phage therapy as an alternative or adjunct to conventional antimicrobials. Expanded access and compassionate use cases have risen exponentially but have varied widely in approach, methodology, and clinical situations in which phage therapy might be considered. Large gaps in knowledge contribute to heterogeneity in approach and lack of consensus in many important clinical areas. The Antibacterial Resistance Leadership Group (ARLG) has convened a panel of experts in phage therapy, clinical microbiology, infectious diseases, and pharmacology, who worked with regulatory experts and a funding agency to identify questions based on a clinical framework and divided them into three themes: potential clinical situations in which phage therapy might be considered, laboratory testing, and pharmacokinetic considerations. Suggestions are provided as answers to a series of questions intended to inform clinicians considering experimental phage therapy for patients in their clinical practices.
KW - Pseudomonas aeruginosa
KW - Staphylococcus aureus
KW - biofilms
KW - phages
UR - http://www.scopus.com/inward/record.url?scp=85123890422&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123890422&partnerID=8YFLogxK
U2 - 10.1128/aac.02071-21
DO - 10.1128/aac.02071-21
M3 - Article
C2 - 35041506
AN - SCOPUS:85123890422
SN - 0066-4804
VL - 66
JO - Antimicrobial agents and chemotherapy
JF - Antimicrobial agents and chemotherapy
IS - 3
M1 - e02071-21
ER -